A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2016
Price : $35 *
At a glance
- Drugs BIIB 061 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 22 Jan 2016 Planned end date changed to May 2016 as per ClinicalTrials.gov record.
- 22 Jan 2016 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.
- 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.